RET and medullary thyroid gland carcinoma: While vandetanib and cabozantinib have been approved by the Food and Drug Administration (FDA) for RET-mutant MTC and RET fusion-positive differentiated thyroid cancer17–19, these inhibitors are not RET-selective and ineffective against RETV804 gatekeeper mutations.